

Update from ECDC FWD

Therese Westrell

Principal expert Food- and waterborne Diseases, ECDC


4th joint meeting on AMR for the FWD-Network and EURL-AR Network, 8-10 June, 2022, Lyngby, Denmark

EFSA-ECDC AMR report



- Report format changed after EFSA's consultation with stakeholders. New format since last three years.
- More condensed, focusing on specific indicators
- Country data moved to annexes
- For FWD-Net, ESBL, AmpC and carbapenemase genes for *Salmonella* collected outside of TESSy today
- Possible to report resistance predicted from WGS and from next year, report sequences to ECDC
- Report outsourced for the first time this year. ECDC maintain data collection and validation internally.
- Presentation of results from 2019/2020 report tomorrow

FWD AMR data in Surveillance Atlas

- AMR data from isolates from humans published in ECDC Surveillance Atlas of Infectious Diseases since last year
- Data on *Salmonella*, *Campylobacter* and *Shigella*
- Select the disease and subpopulation "Antimicrobial resistance"
- Filter on serotype, travel status, antimicrobial and indicator (ECOFFs, clinical breakpoints, "EFSA report" indicator (non-wild type or I+R))
- Resistance rates per country, age, gender and region of travel (for travel-related infections)
- Supporting information can be found under document symbol ()




Surveillance Atlas of Infectious Diseases

Salmonellosis ▾ | Antimicrobial resistance ▾ | S. Enteritidis ▾ | Domestic and unknown ▾ | Ciprofloxacin/pefloxacin ▾

Non-wild type or I+R isolates percentage ▾ | 2020 ▾



Region	Non-wild type or I+R isolates percentage (%)
Norway	19.4
Poland	.
Portugal	4.3
Romania	72.2
Slovakia	13.4
Slovenia	36.6
Spain	12.2
Sweden	22.0
United Kingdom	



Strengthened legal requirement of reporting

EU case definitions (Commission Implementing Decision 2018/945/EU)

In definitions of *Salmonella* and *Campylobacter* enteritidis:

Laboratory Criteria

At least one of the following two:

- Isolation of *Salmonella* (other than *S. Typhi* or *S. Paratyphi*) in a clinical specimen
- Detection of nucleic acid from *Salmonella* (other than *S. Typhi* or *S. Paratyphi*) in a clinical specimen

Note: Antimicrobial susceptibility testing of *Salmonella enterica* should be performed on a representative subset of isolates

Antimicrobial resistance

The results of antimicrobial susceptibility tests must be reported according to the methods and criteria agreed between ECDC and Member States as specified in the EU protocol for harmonised monitoring of antimicrobial resistance in human *Salmonella* and *Campylobacter* isolates ⁽¹⁾.

Intensified laboratory support

- HERA grants for WGS
- EURLs for public health
- HaDEA FWD AMR RefLabCap project 2021-2024
- Update of the [EU protocol for harmonised monitoring of antimicrobial resistance in human Salmonella and Campylobacter isolates](#) on WGS and reporting of genetic determinants - coming
- Phenotypic AST EQA, 8th round started

Reinforced ECDC mandate

In creation of the **European Health Union**, the European Commission proposed to strengthen the legal mandate of ECDC, to improve the European Union's capacity to anticipate, prepare for and manage future cross-border health threats.

- Epidemiological **surveillance** via integrated systems enabling real-time surveillance
- **Preparedness** and **response** planning, reporting and monitoring
- Provision of non-binding **recommendations** for risk management
- Capacity to mobilise and deploy **EU Health Task Force**
- Wider **global reach**
- Network of EU reference **laboratories**



Discussions in this meeting

- How to get representative subset of isolates for antimicrobial susceptibility testing at national public health reference laboratories (FWD-Net session yesterday)
- How to increase completeness of travel status of cases (FWD-Net session today)
 - for better monitoring of travel-related AMR;
 - investigation of emerging clones; and
 - better comparison with food- and animal data
- How to use WGS data for AMR monitoring, including ESBL, AmpC and carbapenemases, investigation of outbreaks and emerging clones (joint session today)

Any questions?

Therese.westrell@ecdc.europa.eu